OPM announces positive results of phase 1 healthy volunteers of OPM-101

OPM announces positive results of phase 1 healthy volunteers of OPM-101:
strong target engagement with excellent safety profile

Dijon (France), July 16, 2024, at 6:00pm CEST– Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announced positive results of phase 1 trial testing the drug candidate OPM-101, administered orally in single ascending doses (SAD) and multiple ascending doses (MAD), in healthy volunteers (HV).